Showing 2541-2550 of 5956 results for "".
- Shamir Announces Changes in Executive Leadershiphttps://modernod.com/news/shamir-announces-changes-in-executive-leadership/2480772/Shamir Insight announced that effective April 1, 2022, Pierson Ball, the company’s Director of Business and Strategic Development has been appointed as the new Vice President of Sales. Mr. Ball joined Shamir in 2007. “I am proud to have been part of the development and
- Opus Enters Strategic Collaboration with Resilience for AAV-based Gene Therapy Development and Manufacturing for Inherited Retinal Diseaseshttps://modernod.com/news/opus-enters-strategic-collaboration-with-resilience-for-aav-based-gene-therapy-development-and-manufacturing-for-inherited-retinal-diseases/2480756/Opus Genetics announced a strategic manufacturing services agreement with National Resilience, a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, to support the development and manufacturing of Opus’ pipeline. Resilience
- AXIM Biotech Develops Rapid Quantitative Tear Test for MMP-9, An Inflammatory Biomarker of Dry Eye Diseasehttps://modernod.com/news/axim-biotech-develops-rapid-quantitative-tear-test-for-mmp-9-an-inflammatory-biomarker-of-dry-eye-disease/2480753/AXIM Biotechnologies announced that it has successfully developed a rapid quantitative tear test for MMP-9, an inflammatory biomarker for dry eye disease. "Dry eye disease, though widespread, is under-diagnosed, in part because symptoms do not always
- Olympic Ophthalmics Announces FDA Clearance and Availability of Its Next-Generation iTEAR100 Neurostimulation Devicehttps://modernod.com/news/olympic-ophthalmics-announces-fda-clearance-and-availability-of-its-next-generation-itear100-neurostimulation-device-expanded-patent-portfolio-and-further-clinical-studies/2480737/Olympic Ophthalmics announced that the FDA has granted 510(K) clearence for its second-generation iTEAR100 device, a prescription neuromodulation therapy to acutely increase tear production in adult patients over a 30-day period. The second-generation device is a connected device o
- Hanita Lenses Launches Joint Venture with Ophthalmic Vision Care in the Iberian Peninsulahttps://modernod.com/news/hanita-lenses-launches-joint-venture-with-ophthalmic-vision-care-in-the-iberian-peninsula/2480732/Hanita Lenses announced a new joint venture with Madrid, Spain-based Ophthalmic Vision Care (OVC), a distributor IOLs for Hanita Lenses in Spain since 2016. The joint venture, named "Hanita Iberica," merges the assets of OVC—as a service provider of d
- FDA Approves Staar Surgical's EVO Visian Implantable Collamer Lenseshttps://modernod.com/news/staar-surgical-announces-fda-approval-of-evo-visian-implantable-collamer-lenses/2480724/Staar Surgical Company announced that the FDA has granted approval of the EVO/EVO+ Visian Implantable Collamer Lens (EVO) for the correction of myopia and myopia with astigmatism. "Following FDA approval, prospective patients in the U.S. and their doctors may n
- SightGlass Vision Announces Andrew Sedgwick as CEO, Names Additional Executive Leadershttps://modernod.com/news/sightglass-vision-announces-andrew-sedgwick-as-ceo-names-additional-executive-leaders/2480716/SightGlass Vision has named three eye care industry veterans to executive leadership positions. This follows the recent finalization of a joint venture operating agreement for the business between CooperCompanies and EssilorLuxottica. Andrew Sedgwick has been appointed as chief exe
- Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa (RP)https://modernod.com/news/kiora-pharmaceuticals-granted-orphan-drug-designation-for-kio-301-an-investigational-drug-for-the-treatment-of-retinitis-pigmentosa-rp/2480706/Kiora Pharmaceuticals has received orphan drug designation from the FDA for its investigational treatment of retinitis pigmentosa, KIO-301. Kiora expects to initiate clinical trials of KIO-301 in Q3 2022. Orphan drug designation provides for facilitated development discussions with the FDA,
- Lumibird Medical Launches New Website Dedicated to Laser Therapies for Each Glaucoma Stagehttps://modernod.com/news/lumibird-medical-launches-new-website-dedicated-to-laser-therapies-for-each-glaucoma-stage/2480684/Lumibird Medical announced the launch of its new website: www.glaucoma-laser-assisted-solutions.com, which details the treatment options at every stage of the disease paradigm: 1. SLT - A first-line treatment for g
- Johnson & Johnson Vision Receives FDA Approval for First Drug-Eluting Contact Lens—Acuvue Theravision with Ketotifenhttps://modernod.com/news/johnson-johnson-vision-receives-fda-approval-for-first-drug-eluting-contact-lens-acuvue-theravision-with-ketotifen/2480676/Johnson & Johnson Vision Care announced that the FDA has approved Acuvue Theravision with Ketotifen (etafilcon A drug-eluting contact lens with ketotifen), the first drug-eluting contact lens. Each lens contains 19 mcg ketotifen, an antihistamine. Acuv